Market Place
Sourcing Support
Cellenkos Showcases CK0804 Phase 1b Data For Myelofibrosis
10 Dec 2024 //
GLOBENEWSWIRE
Cellenkos Announces to Present at ASH on CK0804 in Myelofibrosis
07 Nov 2024 //
PR NEWSWIRE
Cellenkos links with Mount Sinai to explore CK0804 for myelofibrosis
02 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy
19 Feb 2024 //
PR NEWSWIRE
Cellenkos doses first patient in amyotrophic lateral sclerosis trial
03 May 2023 //
CLINICAL TRIALS ARENA
Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy
02 May 2023 //
PR NEWSWIRE
FDA Clears Cellenkos` IND Application for CK0804
16 Jun 2022 //
PRNEWSWIRE
Cellenkos Chooses Cryoport to Support Covid-19 Therapy Shipments to Patients
22 Jun 2021 //
CONTRACTPHARMA
Incyte and Cellenkos Enter into Global Development Collaboration for CK0804
30 Dec 2020 //
BUSINESSWIRE
Incyte and Cellenkos Enter into Global Development Collab Agreement for CK0804
30 Dec 2020 //
BUSINESSWIRE
Cellenkos® Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded
01 Jun 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.